The global Hepatocellular Carcinoma Targeted Drug market size was valued at US$ 1005 million in 2024 and is forecast to a readjusted size of USD 1671 million by 2031 with a CAGR of 7.6% during review period.
The most effective targeted drug introduced for HCC has been听sorafenib. Sorafenib, a multi-tyrosine kinase inhibitor (TKI), remains the only systemic targeted tumor therapy in use for advanced HCC (18-21).
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Hepatocellular Carcinoma Targeted Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Hepatocellular Carcinoma Targeted Drug market size and forecasts, in consumption value ($ Million), 2020-2031
Global Hepatocellular Carcinoma Targeted Drug market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Hepatocellular Carcinoma Targeted Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Hepatocellular Carcinoma Targeted Drug market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Hepatocellular Carcinoma Targeted Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Hepatocellular Carcinoma Targeted Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Eisai, Zelgen, Cipla, Natco Pharma, BEACON Pharma, Jiangxi Shanxiang, Yao Pharma, CSPC, CHIATAI Tianqing, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Hepatocellular Carcinoma Targeted Drug market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Sorafenib
Lenvatinib
Regorafenib
Other
麻豆原创 segment by Application
Hospital
Retail Pharmacy
Other
麻豆原创 segment by players, this report covers
Bayer
Eisai
Zelgen
Cipla
Natco Pharma
BEACON Pharma
Jiangxi Shanxiang
Yao Pharma
CSPC
CHIATAI Tianqing
Simcere
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Hepatocellular Carcinoma Targeted Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Hepatocellular Carcinoma Targeted Drug, with revenue, gross margin, and global market share of Hepatocellular Carcinoma Targeted Drug from 2020 to 2025.
Chapter 3, the Hepatocellular Carcinoma Targeted Drug competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Hepatocellular Carcinoma Targeted Drug market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Hepatocellular Carcinoma Targeted Drug.
Chapter 13, to describe Hepatocellular Carcinoma Targeted Drug research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Hepatocellular Carcinoma Targeted Drug by Type
1.3.1 Overview: Global Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Hepatocellular Carcinoma Targeted Drug Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Sorafenib
1.3.4 Lenvatinib
1.3.5 Regorafenib
1.3.6 Other
1.4 Global Hepatocellular Carcinoma Targeted Drug 麻豆原创 by Application
1.4.1 Overview: Global Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital
1.4.3 Retail Pharmacy
1.4.4 Other
1.5 Global Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size & Forecast
1.6 Global Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast by Region
1.6.1 Global Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business
2.1.3 Bayer Hepatocellular Carcinoma Targeted Drug Product and Solutions
2.1.4 Bayer Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Bayer Recent Developments and Future Plans
2.2 Eisai
2.2.1 Eisai Details
2.2.2 Eisai Major Business
2.2.3 Eisai Hepatocellular Carcinoma Targeted Drug Product and Solutions
2.2.4 Eisai Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Eisai Recent Developments and Future Plans
2.3 Zelgen
2.3.1 Zelgen Details
2.3.2 Zelgen Major Business
2.3.3 Zelgen Hepatocellular Carcinoma Targeted Drug Product and Solutions
2.3.4 Zelgen Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Zelgen Recent Developments and Future Plans
2.4 Cipla
2.4.1 Cipla Details
2.4.2 Cipla Major Business
2.4.3 Cipla Hepatocellular Carcinoma Targeted Drug Product and Solutions
2.4.4 Cipla Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Cipla Recent Developments and Future Plans
2.5 Natco Pharma
2.5.1 Natco Pharma Details
2.5.2 Natco Pharma Major Business
2.5.3 Natco Pharma Hepatocellular Carcinoma Targeted Drug Product and Solutions
2.5.4 Natco Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Natco Pharma Recent Developments and Future Plans
2.6 BEACON Pharma
2.6.1 BEACON Pharma Details
2.6.2 BEACON Pharma Major Business
2.6.3 BEACON Pharma Hepatocellular Carcinoma Targeted Drug Product and Solutions
2.6.4 BEACON Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 BEACON Pharma Recent Developments and Future Plans
2.7 Jiangxi Shanxiang
2.7.1 Jiangxi Shanxiang Details
2.7.2 Jiangxi Shanxiang Major Business
2.7.3 Jiangxi Shanxiang Hepatocellular Carcinoma Targeted Drug Product and Solutions
2.7.4 Jiangxi Shanxiang Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Jiangxi Shanxiang Recent Developments and Future Plans
2.8 Yao Pharma
2.8.1 Yao Pharma Details
2.8.2 Yao Pharma Major Business
2.8.3 Yao Pharma Hepatocellular Carcinoma Targeted Drug Product and Solutions
2.8.4 Yao Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Yao Pharma Recent Developments and Future Plans
2.9 CSPC
2.9.1 CSPC Details
2.9.2 CSPC Major Business
2.9.3 CSPC Hepatocellular Carcinoma Targeted Drug Product and Solutions
2.9.4 CSPC Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 CSPC Recent Developments and Future Plans
2.10 CHIATAI Tianqing
2.10.1 CHIATAI Tianqing Details
2.10.2 CHIATAI Tianqing Major Business
2.10.3 CHIATAI Tianqing Hepatocellular Carcinoma Targeted Drug Product and Solutions
2.10.4 CHIATAI Tianqing Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 CHIATAI Tianqing Recent Developments and Future Plans
2.11 Simcere
2.11.1 Simcere Details
2.11.2 Simcere Major Business
2.11.3 Simcere Hepatocellular Carcinoma Targeted Drug Product and Solutions
2.11.4 Simcere Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 Simcere Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Hepatocellular Carcinoma Targeted Drug Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Hepatocellular Carcinoma Targeted Drug by Company Revenue
3.2.2 Top 3 Hepatocellular Carcinoma Targeted Drug Players 麻豆原创 Share in 2024
3.2.3 Top 6 Hepatocellular Carcinoma Targeted Drug Players 麻豆原创 Share in 2024
3.3 Hepatocellular Carcinoma Targeted Drug 麻豆原创: Overall Company Footprint Analysis
3.3.1 Hepatocellular Carcinoma Targeted Drug 麻豆原创: Region Footprint
3.3.2 Hepatocellular Carcinoma Targeted Drug 麻豆原创: Company Product Type Footprint
3.3.3 Hepatocellular Carcinoma Targeted Drug 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Hepatocellular Carcinoma Targeted Drug Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Hepatocellular Carcinoma Targeted Drug 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Hepatocellular Carcinoma Targeted Drug Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Hepatocellular Carcinoma Targeted Drug 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Hepatocellular Carcinoma Targeted Drug Consumption Value by Type (2020-2031)
6.2 North America Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size by Application (2020-2031)
6.3 North America Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size by Country
6.3.1 North America Hepatocellular Carcinoma Targeted Drug Consumption Value by Country (2020-2031)
6.3.2 United States Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Hepatocellular Carcinoma Targeted Drug Consumption Value by Type (2020-2031)
7.2 Europe Hepatocellular Carcinoma Targeted Drug Consumption Value by Application (2020-2031)
7.3 Europe Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size by Country
7.3.1 Europe Hepatocellular Carcinoma Targeted Drug Consumption Value by Country (2020-2031)
7.3.2 Germany Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Hepatocellular Carcinoma Targeted Drug Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Hepatocellular Carcinoma Targeted Drug Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size by Region
8.3.1 Asia-Pacific Hepatocellular Carcinoma Targeted Drug Consumption Value by Region (2020-2031)
8.3.2 China Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Hepatocellular Carcinoma Targeted Drug Consumption Value by Type (2020-2031)
9.2 South America Hepatocellular Carcinoma Targeted Drug Consumption Value by Application (2020-2031)
9.3 South America Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size by Country
9.3.1 South America Hepatocellular Carcinoma Targeted Drug Consumption Value by Country (2020-2031)
9.3.2 Brazil Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Hepatocellular Carcinoma Targeted Drug Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Hepatocellular Carcinoma Targeted Drug Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size by Country
10.3.1 Middle East & Africa Hepatocellular Carcinoma Targeted Drug Consumption Value by Country (2020-2031)
10.3.2 Turkey Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Hepatocellular Carcinoma Targeted Drug 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Hepatocellular Carcinoma Targeted Drug 麻豆原创 Drivers
11.2 Hepatocellular Carcinoma Targeted Drug 麻豆原创 Restraints
11.3 Hepatocellular Carcinoma Targeted Drug Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Hepatocellular Carcinoma Targeted Drug Industry Chain
12.2 Hepatocellular Carcinoma Targeted Drug Upstream Analysis
12.3 Hepatocellular Carcinoma Targeted Drug Midstream Analysis
12.4 Hepatocellular Carcinoma Targeted Drug Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Bayer
Eisai
Zelgen
Cipla
Natco Pharma
BEACON Pharma
Jiangxi Shanxiang
Yao Pharma
CSPC
CHIATAI Tianqing
Simcere
听
听
*If Applicable.
